biote (BTMD) Stock Analysis & Winston Score

Biote Corp. trains doctors and other healthcare providers to offer hormone optimization therapy, mainly using small pellets implanted under the skin. These pellets slowly release hormones like testosterone and estrogen to help patients — mostly middle-aged adults — manage symptoms of hormonal decline. The company operates in the United States and works with a network of certified medical practices that use the Biote method. Biote makes money by selling hormone pellets and dietary supplements to its network of provider clinics, which pay for training and then purchase supplies on an ongoing basis. The company has built a recurring revenue stream because certified providers keep buying products as long as patients continue treatment. With a market cap of around $100 million, Biote is a small player in the broader hormone therapy space, and its main risk is regulatory scrutiny — compounded hormone pellets face ongoing oversight from the FDA, which could restrict how these products are made or marketed.